EcoDrugPlus

Oxytocin Receptor A

Ensembl ID : ENSOSIG00000011034
Gene Symbol: OXTRA
1 Cross references
191 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSOSIG00000013841
Gene Symbol: PAK4
1 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOSIG00000015179
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOSIG00000006806
Gene Symbol: PPARG
1 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSOSIG00000022135
Gene Symbol: PPARAA
1 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSOSIG00000021542
Gene Symbol: PPARAB
1 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSOSIG00000019931
Gene Symbol: PPARDB
1 Cross references
392 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOSIG00000010753
Gene Symbol: PIK3CA
1 Cross references
181 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOSIG00000004181
Gene Symbol: PIK3CA
1 Cross references
208 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSOSIG00000018838
Gene Symbol: PIK3CB
1 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSOSIG00000022960
Gene Symbol: PIK3CD
1 Cross references
211 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSOSIG00000000525
Gene Symbol: PIK3CG
1 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).